159 related articles for article (PubMed ID: 16469875)
21. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1).
Turturro F; Frist AY; Arnold MD; Seth P; Pulford K
Oncogene; 2001 Jul; 20(33):4466-75. PubMed ID: 11494142
[TBL] [Abstract][Full Text] [Related]
22. An osteoclastic protein-tyrosine phosphatase regulates the β3-integrin, syk, and shp1 signaling through respective src-dependent phosphorylation in osteoclasts.
Lau KH; Stiffel V; Amoui M
Am J Physiol Cell Physiol; 2012 Jun; 302(11):C1676-86. PubMed ID: 22460711
[TBL] [Abstract][Full Text] [Related]
23. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.
Slupianek A; Skorski T
Exp Hematol; 2004 Dec; 32(12):1265-71. PubMed ID: 15588951
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
[TBL] [Abstract][Full Text] [Related]
26. NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis.
McDonnell SR; Hwang SR; Basrur V; Conlon KP; Fermin D; Wey E; Murga-Zamalloa C; Zeng Z; Zu Y; Elenitoba-Johnson KS; Lim MS
Oncogene; 2012 Aug; 31(32):3733-40. PubMed ID: 22179823
[TBL] [Abstract][Full Text] [Related]
27. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
[TBL] [Abstract][Full Text] [Related]
28. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
29. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.
Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D
Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382
[TBL] [Abstract][Full Text] [Related]
30. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
[TBL] [Abstract][Full Text] [Related]
31. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
[TBL] [Abstract][Full Text] [Related]
32. Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase.
Bacchiocchi R; Baldanzi G; Carbonari D; Capomagi C; Colombo E; van Blitterswijk WJ; Graziani A; Fazioli F
Blood; 2005 Sep; 106(6):2175-82. PubMed ID: 15928040
[TBL] [Abstract][Full Text] [Related]
33. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
34. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
35. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
[TBL] [Abstract][Full Text] [Related]
36. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
37. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
39. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984
[TBL] [Abstract][Full Text] [Related]
40. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]